RxDoctor Payments Data

Melissa Bollinger

Optometrist · Lake Villa, ILNPI 1578640215

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 36.7% of the total. 2025 is the largest year on record at $22,029, 9.0 times the $2,452 reported in 2019. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$81,952in general payments, 2019–2025

Across 294 payments — averaging $278.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$30K
  • Alcon$21K
  • Oyster Point Pharma, Inc.$15K
  • Ocular Therapeutix, Inc.$6K
  • Sight Sciences, Inc.$3K
  • Novartis$2K
  • plus $5K from 22 others
$84,829in research payments, 2019–2025

Across 5 payments — averaging $16,966 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$82K
  • Ocular Therapeutix, Inc.$2K

What the payments were for

  • Consulting fees$24,83530%
  • Speaking & faculty fees$38,78047%
  • Travel & lodging$9,69812%
  • Food & beverage$8,63911%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,952 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$145,121
Medicare patients
617
Services billed
1,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine59$53,769
XiidraLifitegrast49$41,982
LumiganBimatoprost63$30,307
MieboPerfluorohexyloctane/Pf25$21,300
TyrvayaVarenicline Tartrate21$16,231
Cyclosporine23$9,579
Travoprost13$3,291
Latanoprost150$1,546
Loteprednol Etabonate11$1,157
Prednisolone Acetate12$690
Brimonidine Tartrate15$581
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat57$564
Azelastine Hcl23$484
Dorzolamide Hcl17$436
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha42$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$324$84,076122 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$30,067$63,28274 claims
Oyster Point Pharma, Inc.Tyrvaya$14,610$16,23121 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$68$1,15711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.

Other optometrist in Lake Villa

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →